West Pharmaceutical Services (NYSE: WST) filed its 10-K on Feb. 29. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), West Pharmaceutical Services beat slightly on revenue and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share grew significantly.

Margins grew across the board.

Revenue details
West Pharmaceutical Services booked revenue of $295.4 million. The two analysts polled by S&P Capital IQ expected net sales of $290.1 million on the same basis. GAAP reported sales were 6.7% higher than the prior-year quarter's $276.8 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $0.59. The four earnings estimates compiled by S&P Capital IQ predicted $0.55 per share on the same basis. GAAP EPS of $0.54 for Q4 were 157% higher than the prior-year quarter's $0.21 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 28.9%, 70 basis points better than the prior-year quarter. Operating margin was 10.1%, 270 basis points better than the prior-year quarter. Net margin was 6.4%, 420 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $308.2 million. On the bottom line, the average EPS estimate is $0.65.

Next year's average estimate for revenue is $1.22 billion. The average EPS estimate is $2.47.

Investor sentiment
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on West Pharmaceutical Services is hold, with an average price target of $44.00.

The healthcare investing landscape is littered with also-rans and a few major winners. Is West Pharmaceutical Services performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.